Consequences of Brexit on Biosimilars

With Europe that made-up because of the uptake of biosimilars over a decade agone, the results of Brexit would be doubtless tougher on UK. Presently UK isn't to any extent further guaranteed to follow the foundations of EMA. Additionally analysis grants from Innovative Medicines Initiative and Horizon 2020 would no a lot of be offered to UK. All the same, EMA has its headquarters in London, UK. The so arising complications would positively have sure consequences on the Biosimilars state of affairs in UK and EU.

  • Brexit- Pros and Cons to European pharma market
  • Post Brexit changes in biosimilars regulation in UK
  • Fate of biosimilars clinical trials in UK
  • Research funding from European organizations to UK based research laboratories

Related Conference of Consequences of Brexit on Biosimilars

November 27-27, 2021

Drug Formulation Bioavailability 2021

London, UK
February 07-08, 2022

World Congress on Pharmaceutical Chemistry

Paris, France

Consequences of Brexit on Biosimilars Conference Speakers

Recommended Sessions

Related Journals

Are you interested in